427 related articles for article (PubMed ID: 16990857)
21. Cutaneous reactions to epidermal growth factor receptor inhibitors.
Pomerantz RG; Mirvish ED; Geskin LJ
J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
[TBL] [Abstract][Full Text] [Related]
22. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway.
MacLaine NJ; Wood MD; Holder JC; Rees RW; Southgate J
Mol Cancer Res; 2008 Jan; 6(1):53-63. PubMed ID: 18234962
[TBL] [Abstract][Full Text] [Related]
24. Biology of interactions: antiepidermal growth factor receptor agents.
Harari PM; Allen GW; Bonner JA
J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
[TBL] [Abstract][Full Text] [Related]
25. Dermatologic toxicities of targeted anticancer therapies.
Balagula Y; Lacouture ME; Cotliar JA
J Support Oncol; 2010; 8(4):149-61. PubMed ID: 20822032
[TBL] [Abstract][Full Text] [Related]
26. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
[TBL] [Abstract][Full Text] [Related]
27. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
28. Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?
Rodeck U
J Cell Physiol; 2009 Jan; 218(1):32-4. PubMed ID: 18781585
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetics of EGFR and VEGF inhibition.
Pander J; Gelderblom H; Guchelaar HJ
Drug Discov Today; 2007 Dec; 12(23-24):1054-60. PubMed ID: 18061885
[TBL] [Abstract][Full Text] [Related]
30. Review: side effects of approved molecular targeted therapies in solid cancers.
Widakowich C; de Castro G; de Azambuja E; Dinh P; Awada A
Oncologist; 2007 Dec; 12(12):1443-55. PubMed ID: 18165622
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular toxicity of molecularly targeted agents.
Strevel EL; Siu LL
Eur J Cancer; 2009 Sep; 45 Suppl 1():318-31. PubMed ID: 19775628
[No Abstract] [Full Text] [Related]
32. Mechanisms for oncogenic activation of the epidermal growth factor receptor.
Zandi R; Larsen AB; Andersen P; Stockhausen MT; Poulsen HS
Cell Signal; 2007 Oct; 19(10):2013-23. PubMed ID: 17681753
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapies in colorectal carcinoma: addressing toxicities associated with EGFR inhibitors.
Biedrzycki BA
ONS Connect; 2007; 22(8 Suppl):33-4. PubMed ID: 17824555
[No Abstract] [Full Text] [Related]
35. Skin toxicities of targeted therapies.
Segaert S; Chiritescu G; Lemmens L; Dumon K; Van Cutsem E; Tejpar S
Eur J Cancer; 2009 Sep; 45 Suppl 1():295-308. PubMed ID: 19775626
[No Abstract] [Full Text] [Related]
36. Clinical management of EGFRI dermatologic toxicities: US perspective.
Lacouture ME; Cotliar J; Mitchell EP
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
[TBL] [Abstract][Full Text] [Related]
37. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.
Boucher J; Olson L; Piperdi B
Clin J Oncol Nurs; 2011 Oct; 15(5):501-8. PubMed ID: 21951736
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
[TBL] [Abstract][Full Text] [Related]
39. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
Segaert S; Van Cutsem E
Ann Oncol; 2005 Sep; 16(9):1425-33. PubMed ID: 16012181
[TBL] [Abstract][Full Text] [Related]
40. The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): a new tool for grading and managing skin adverse reactions to epidermal growth factor receptor inhibitors.
Lisi P; Bellini V; Bianchi L
Oncology; 2014; 87(5):311-9. PubMed ID: 25196815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]